Adjusting Pacemaker Heart Rate Settings in People With Heart Failure
Tests individualized pacemaker rate settings against the usual 60bpm in heart failure.
Key facts
- Who runs it
- Samsung Medical Center
- Where
- Seoul, South KoreaSee the site
- Trial code
- NCT07563153
- KCT0010987
- Registry title
- Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker
- Status
- Recruiting
- People taking part
- 106 people, planned
- Started
- 18 Dec 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Adjustment of the pacemaker/ICDs lower rate limit (LRL)
- Conventional lower rate (60bpm)
- Record updated
- 1 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure who need a permanent pacemaker because of a slow heart rate. It tests an individualized pacemaker lower rate setting against the usual one.
- Age
- 19 years and older
- Sex
- All sexes can join.
- Disease stage
- Slow heart rate with symptoms who meet the indication for a permanent pacemaker (sick sinus syndrome, persistent or permanent atrial fibrillation with slow ventricular response, or chronotropic incompetence), plus heart failure with left ventricular ejection fraction ≥ 50%.
- Earlier treatment
- Not stated, except that heart failure must be shown by one of: a prior hospital stay for heart failure, or use of loop diuretics for heart failure symptoms (or a high score or blood test, see below).
- Biomarker or test result
- Heart failure must be shown by at least one of: H2FPEF score ≥ 6, HFA-PEFF score ≥ 5, or N-terminal pro-B-type natriuretic peptide ≥ 300 pg/mL (sinus rhythm) or ≥ 600 pg/mL (atrial fibrillation).
Main reasons for not taking part
- Expected ventricular pacing ≥ 20% without sufficient physiologic pacing (paced QRS duration ≤ 140 ms)
- Not expected to depend enough on pacing (baseline rate > 60 bpm)
- Contraindication to a permanent pacemaker
- Moderate or greater valve narrowing or leakage
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients with symptomatic bradycardia who meet the indication for permanent pacemaker implantation and fulfill one of the following conditions:; Sick sinus syndrome with or without impaired atrioventricular conduction; Persistent or permanent atrial fibrillation with slow ventricular response; Chronotropic incompetence
- Patients diagnosed with heart failure with left ventricular ejection fraction ≥ 50% on transthoracic echocardiography with at least one of the following:
- H2FPEF score ≥ 6 or HFA-PEFF score ≥ 5
- N-terminal pro-B-type natriuretic peptide ≥ 300 pg/mL (sinus rhythm) or ≥ 600 pg/mL (atrial fibrillation)
- Prior hospitalization for heart failure or documented use of loop diuretics for heart failure symptoms
Who cannot take part
- Patients expected to have a ventricular pacing burden ≥ 20% without sufficient capture of cardiac physiologic pacing, which includes biventricular pacing, His bundle pacing, and left bundle branch area pacing; (Sufficient cardiac physiologic pacing is defined as a paced QRS duration ≤ 140 ms.)
- Patients with dyspnea not attributable to heart failure, due to uncontrolled comorbid conditions
- Patients not expected to achieve sufficient pacing dependency, defined as:; In sinus rhythm: baseline atrial rate > 60 bpm on Holter monitoring or inpatient ECG monitoring; In atrial fibrillation/flutter: baseline ventricular rate > 60 bpm on Holter monitoring or inpatient ECG monitoring
- Patients with contraindications to permanent pacemaker implantation
- Patients with moderate or greater valvular stenosis or regurgitation
- Pregnant or breastfeeding women
- Patients who have refused active treatment
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaContact: Juwon Kim, MDTaking people
About the trial
What the trial wants to find out
This study aims to evaluate the clinical impact of an optimized pacing strategy in patients with heart failure.
Read full original descriptionShow less
* Intervention: Adjustment of the pacemaker lower rate limit to an individualized, hemodynamically optimized heart rate. * Primary Endpoint: Heart failure symptoms, assessed by the Kansas City Cardiomyopathy Questionnaire score. * Hypothesis: In patients with heart failure requiring permanent pacing, an optimized pacing strategy will lead to a significant improvement in heart failure symptoms (Kansas City Cardiomyopathy Questionnaire score) at 12 months compared with the conventional pacing strategy.
The 2 groups in the trial
- Optimized pacing strategyTreatment being tested
Optimized Pacing Strategy * Definition of Optimal Heart Rate: After permanent pacemaker implantation, a hemodynamic evaluation will be performed using right heart catheterization with stepwise incremental pacing rates of 60, 70, 80, and 90 bpm. If the optimal heart rate is identified at one of these 10-bpm intervals, additional assessments will be conducted in 5-bpm increments around that rate to further refine the optimal pacing rate. * Invasive hemodynamic parameters assessed include: Mean pulmonary capillary wedge pressure, Cardiac output (thermodilution) * The optimal heart rate is defined as the pacing rate associated with the lowest mean pulmonary capillary wedge pressure or highest cardiac output. * To ensure hemodynamic stabilization, a 5-minute washout period will be applied between rate changes. * To minimize the confounding effects of intrinsic bradycardia below 60 bpm, optimized pacing will be performed after a stabilization period of 2 weeks following permanent pacemaker.
Treatment: Adjustment of the pacemaker/ICDs lower rate limit (LRL)
- Conventional pacing strategyExisting treatment, for comparison
Conventional Pacing Strategy • The conventional pacing group will have the pacemaker's lower rate limit set at a fixed 60 bpm, in accordance with current standard practice.
Treatment: Conventional lower rate (60bpm)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical and Hemodynamic Outcomes of OPTimized PACing StratEgies in Heart Failure Patients With Pacing Indications: Randomized-Controlled Trial (OPTPACE-HF)
- Plain-language title
- Adjusting Pacemaker Heart Rate Settings in People With Heart FailureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 May 2026